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INTRODUCTION: The Shwachman-Kulczycki score was the first scoring system used in cystic fibrosis to assess disease
severity. Despite its subjectivity, it is still widely used.
OBJECTIVE: To study correlations among forced expiratory volume in one second (FEV1), chest radiography, chest
computed tomography, 6-minute walk test, and Shwachman-Kulczycki score in patients with cystic fibrosis and to
test whether the Shwachman-Kulczycki score is still useful in monitoring the severity of the disease.
METHODS: A cross-sectional prospective study was performed to analyze the correlations (Spearman). Patients with
clinically stable cystic fibrosis, aged 3-21 years, were included.
RESULTS: 43 patients, 19F/24M, mean age 10.5 ¡ 4.7 years, with a median Shwachman-Kulczycki score of 70 were
studied. The median Brasfield and Bhalla scores were 17 and 10, respectively. The mean Z score for the 6-minute
walk test was 21.1 ¡ 1.106 and the mean FEV1 was 59 ¡ 26 (as percentage of predicted values). The following
significant correlations versus the Shwachman-Kulczycki score were found: FEV1 (r = 0.76), 6-minute walk test (r =
0.71), chest radiography (r = 0.71) and chest computed tomography (r = 20.78). When patients were divided
according to FEV1, a statistically significantly correlation with the Shwachman-Kulczycki score was found only in
patients with FEV1 ,70% (r = 0.67).
CONCLUSIONS: The Shwachman-Kulczycki score remains an useful tool for monitoring the severity of cystic fibrosis,
adequately reflecting the functional impairment and chest radiography and tomography changes, especially in
patients with greater impairment of lung function. When assessing patients with mild lung disease its limitations
should be considered and its usefulness in such patients should be evaluated in larger populations.
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INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal
recessive hereditary disease in the Caucasian population. It
is characterized by suppurative chronic obstructive pulmon-
ary disease, pancreatic insufficiency, multifocal biliary
cirrhosis and electrolyte loss in sweat. In men, CF is also
associated with infertility due to obstructive azospermia.1-3
Disease progression is assessed through tests of pulmon-
ary function, chest radiography and tomography, and
clinical data. However, the scores used to assess disease
severity in CF were developed some time ago and may not
meet current needs.4
The Shwachman-Kulczycki (SK) score, published in 1958,
was the first score to assess the severity of CF.5 It was
developed based on a study which monitored 105 patients
for 5 years, exposing the need for a system to evaluate the
severity of this disease, and to provide a perception of the
overall clinical status of the patient. This score is based on
clinical and radiological evaluation and represented a
milestone in the history of CF. Since its publication many
other scoring systems for different aspects of CF have been
developed, mainly radiological, functional and clinical
scores. However, the SK score is still the most widely used
score, despite its subjectivity, lack of systematic application
and its failure to consider the lung function test.
In this study we investigated the correlation between the
SK score and other current parameters used to evaluate CF
severity, such as forced expiratory volume in 1 second
(FEV1), 6-minute walk test (6-MWT), chest radiography
(CXR) and chest computed tomography (CT). Our aim was
to evaluate the current usefulness of the SK score in view of
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the fact that a greater number of patients are now being
detected at earlier stages of disease and thus present a
milder version of the disease than patients in later stages.
MATERIALS AND METHODS
This was a cross-sectional prospective study. Data from
clinical charts, radiological documents (CXR and CT), 6-MWT
and spirometry of 43 patients with cystic fibrosis aged between
3 and 21 years and treated at the Cystic Fibrosis Center of
Instituto da Crianc¸a – Hospital das Clı´nicas (Sa˜o Paulo, Brazil)
between June 2006 and August 2008 were analyzed. The
diagnosis of CF was made according to established criteria.6
Only patients with stable disease were included in this study.
Exclusion criteria were pulmonary exacerbation7 in the month
preceding the tests or a chest CT carried out in the previous
year. Spirometry, chest radiography and CT and the 6-MWT
were all carried out on the same morning.
Of the 114 patients followed up at our CF clinic who were
eligible for inclusion during the period of the study, 43
fulfilled all inclusion criteria and therefore comprise a
convenience sample.
Shwachman-Kulczycki score
The SK score was calculated by two pediatric pulmonol-
ogists with expertise in CF. The SK score is divided into four
domains—namely, general activity; physical examination;
nutrition; and radiological findings; each having five
possible subscores, according to the degree of impairment.
The scores of the four domains are summed to obtain the
final score, from which the condition of the patient is
categorized as excellent (86-100), good (71-85), average (56-
70), poor (41-55) or severe (#40).
Pulmonary Function Test
Spirometry was performed at the pulmonary function
laboratory of Instituto da Crianc¸a in patients over 6 years,
following the recommendations of the American Thoracic
Society (ATS)8 and using a master screen spirometer
(Multispiro Creative Biomedics) (Natick, MA, United States).
The following spirometric parameters were evaluated: forced
vital capacity, FEV1 and forced expiratory flow between 25
and 75% of vital capacity as a percentage of predicted values.
The equations of Polgar and Promadhat9 were used as a
reference for subjects up to 17 years of age, and the equation of
Knudson et al.10 was used for patients aged between 18 and 21
years. The severity of the ventilatory obstruction was classified
according to ATS criteria.8
Patients were divided into two groups according to FEV1:
, 70% and $ 70%. Patients with FEV1 $ 70% were
considered as having mild lung disease.
Chest Radiography
The Brasfield score,11 which considers 5 categories scored
from 0 to 5—namely, air trapping, linear markings, nodular
cystic lesions, large lesions and general severity, was used to
evaluate CXR changes. The demerit points were then
summed and subtracted from 25 to obtain the final score.
Chest roentgenograms showing more severe changes
received a lower score.
Chest CT Scan
The Bhalla score was used for tomographic analysis.12
This score was calculated using nine categories—namely,
severity of bronchiectasis, peribronchial thickening, extent
of bronchiectasis, extent of mucus plugging, saculations or
abscesses, generation of bronchial divisions involved,
number of bullae, emphysema and collapse or consolida-
tion. These categories were scored from 0 to 3, with a higher
score indicating greater structural damage.
Scanning was performed with a GE LightSpeed Ultra CT
Scanner (Minneapolis, USA). Thin-section CT scans were
obtained using a beam current automatically adjusted by
the machine (70-100 mA), an exposure time of 0.5 seconds, a
beam potential of 120 kV from lung apex to lung base at
10 mm intervals using 1.25 mm thick single slices, non-
volumetric and a field of view of 15-40 cm. All scans were
reconstructed with a high spatial frequency algorithm
(bone) and printed with window settings appropriate for
the imaging of pulmonary parenchyma (window width -
600 HU; window level 1.500 HU).
The radiographic and tomographic scores were calculated
independently by three radiologists (two pediatric radiolo-
gists and a chest radiologist), who were blinded to the
clinical and functional characteristics of the patients. The
final score was the average of the three radiologists’ scores.
Six-Minute Walk Test
All 6-MWTs were done using a 30 m lap, on a flat, hard
surface, according to the ATS guidelines.13 The patients
were asked to walk for 6 minutes up and down the
measured lap at their best pace, but not to run. Two tests
were performed on the same day with an interval of at least
30 min and after all clinical variables had returned to their
basal values. The distance was measured in meters and the
test with the greatest distance was selected. The values were
transformed into Z scores based on Geiger et al. data,14
using the following formula: value found – normal value/
standard deviation.
Statistical Analysis
Data were expressed as number of cases, mean and
standard deviation or median. Linear regression (Spearman’s
correlation coefficient) was used for analysis of correlations
between the tests, calculated by the GraphPadPrism 5
program. The significance level considered was p , 0.05.
This study was approved by the human ethics committee
of Hospital das Clı´nicas – Medical School of University of
Table 1 - Characteristics of the patients (24 men, 19
women) with cystic fibrosis (n = 43).
Characteristics M ¡ SD R
Age (years) 10.5¡4.7 3.1-20.9
BMI-Z -0.7¡1.2 -2.9-2.1
Z-6-MWT * -1.1¡1.1 -4.07-0.6
FVC (% predicted)* 70.4¡25.9 20.4-126
FEV1 (% predicted)* 59.2¡26 13.3-134.0
FEF25-75% (% predicted)* 47.4¡35.8 4.8-172.4
Bhalla score (median) 10.0 2.3-19
Brasfield score (median)
Shwachman-Kulczycki score
(median)
17.0
70
6-23.7
40-95
*n = 34.
BMI-Z = Z score of body mass index; FEF25-75% = forced expiratory flow
between 25 and 75% of vital capacity; FEV1 = forced expiratory volume in
1 second, FVC = forced vital capacity; Z-6-MWT = Z score of 6-minute
walk test.
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Sa˜o Paulo, Brazil. Written informed consent was obtained
from all subjects or their parents.
RESULTS
Forty-three patients were studied, 19 female and 24 male,
mean age 10.5¡ 4.7 years. The characteristics of the patients
are listed in Table 1. Patients’ average body mass index
(BMI) was 16.5¡ 2.4 and their BMI Z score was –0.7¡ 1.2.
Pulmonary function tests showed that 11 children had mild
obstructive lung disease (FEV1 $ 70%) or normal FEV1
(FEV1 $ 80%), seven moderate (FEV1 = 60-69%), five
moderately severe (FEV1 = 50-59%), six severe (FEV1 = 35-
49%) and five very severe (FEV1 # 35%) disease.
The mean distance walked was 596 ¡ 69 m and the Z
score of the 6-MWT was 21.1 ¡ 1.106.
Figure 1 - (A) Correlation between the Bhalla score and the Shwachman-Kulczycki score; (B) correlation between FEV1 and Shwachman-
Kulczycki score; (C) correlation between the Brasfield score and Shwachman-Kulczycki score; (D) correlation between the 6-MWT and
Shwachman-Kulczycki score; (E) correlation between FEV1 , 70% and $ 70% and the Shwachman-Kulczycki Score. FEV1 = forced
expiratory volume in 1 second; 6-MWT = 6-minute walk test.
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For all patients the correlations between the SK score and
Brasfield and Bhalla scores were calculated. In 34 patients
aged . 6 years it was possible to calculate the correlations
between SK score and FEV1 and between SK score and Z-6-
MWT. A significant correlation between all parameters was
observed (Figures 1A-D).
When patients were divided into two groups according to
FEV1 (, 70% and $ 70%), a statistically significantly
correlation was found between FEV1 and the SK score only
in patients with FEV1 , 70% (Figure 1E).
DISCUSSION
In this study, the SK score correlated strongly and
significantly with FEV1, chest radiography and tomography
and with the 6-MWT. The significant correlations between
the SK score and chest CT, and between the SK score and 6-
MWT, are novel findings reported in this study.
Previous studies showed strong correlations between the
SK score and pulmonary function tests (r values ranging
from 0.63 to 0.72 for FEV1).
15-17
Similar to our findings and despite having a better FEV1,
two retrospective studies in patients with CF in Brazil also
found significant correlations between the SK score and
FEV1 (r = 0.5 and 0.75).
18,19
To test if a strong correlation still exists between FEV1 and
the SK score for the severity of lung function impairment,
patients were divided according to the degree of pulmonary
involvement indicated by FEV1. The correlation between
FEV1 and the SK score was significant only in patients with
FEV1 , 70% (r = 0.67, p = 0.0003), whereas in patients with
FEV1 $ 70% no correlation with the SK score was found (r
= 20.04).
One previous study tested a correlation between the 6-
MWT and the SK score in 16 children with CF, aged 11 ¡
1.9 years, with an FEV1 of 63.1¡21%, SK score of 69.4¡ 16
and 6-MWT of 598.2 ¡ 56.8 m.20 Despite the similar
characteristics of their patients to those of our study, no
significant correlation was found, possibly owing to the
smaller number of patients in their study than in ours.
Another study also found no significant correlation between
the 6-MWT and the SK score but in that study adolescents
and adults with CF were evaluated,21 which might account
for the lack of correlation, because age is one of the sources
of the 6-MWT variations, as reported in other studies.14,22,23
Although reference values for 6-MWT in Brazilian
children have recently been published22 we decided to use
those of Geiger et al.14 because our sample comprised
patients up to 21 years old and the Brazilian data only
included patients aged , 12 years. Nevertheless, the
Brazilian data on reference values for the 6-MWT strongly
correlated with the data of Geiger et al. (r = 0.87).
Correlations between the SK score and chest radiography
have been observed since the late 1970s. Brasfield et
al.11observed a significant correlation between the SK score
and chest radiography (r = 0.82, p , 0001), while
evaluating 643 chest radiographs of 118 patients with CF.
Note that the correlation they found is higher than that
found in our study (r = 0.71). Freire et al.19 while evaluating
40 children with CF also found a significant correlation
between the SK score and the Brasfield score (r = 0.62). The
highest correlation observed in our study was between the
SK score and CT (r = 20.78, p , 0.001). This correlation has
not been previously described.
One limitation of our study is that it was cross-sectional,
which precludes a longitudinal evaluation. Despite the high
correlation found in our study between the SK score and
both imaging and functional pulmonary data, it was not
possible to assess whether or not the parameters (CXR, CT,
FEV1, 6-MWT and SK score) changed in a similar way.
The SK clinical score is criticized because it depends on
the subjective clinical estimation of the examiner and lacks a
domain that evaluates pulmonary function. Some authors
even claim that because the SK score was developed in an
era when patients were detected later and thus presented
more severe disease, it is unlikely to be sufficiently sensitive
to describe the spectrum of clinical features of milder
disease; this is a great limitation of the SK clinical score in
comparison with other evaluations. Our data indicate that
the SK score may be more reliable in assessing the severity
of CF in patients with greater impairment of lung function,
reinforcing this limitation. However, it strongly correlated
with other important outcome measurements currently
used, such as radiographic and tomographic scores and
the 6-MWT. Another limitation of the SK score is that its
development was based on pediatric patients and some of
the domains are specifically focused on children.
Nevertheless, it is still used in many CF clinics and studies,
even in older patients.18,19,24
CONCLUSION
In conclusion, the SK score remains a useful and simple
tool for monitoring the severity of CF, adequately reflecting
the functional impairment and chest radiography and
tomography changes, especially in patients with greater
impairment of lung function. When assessing patients with
mild lung disease its limitations should be considered and
its usefulness in such patients should be evaluated in larger
populations.
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